Fulgent Genetics Business Summary

Fulgent Genetics, Inc. (FLGT) operates a technology-driven precision medicine platform, generating revenue primarily through a transaction-based model for clinical diagnostic testing and biopharma services. The company’s business is organized into three core laboratory segments: Precision Diagnostics, which provides comprehensive genetic testing for oncology and reproductive health; Anatomic Pathology, significantly expanded in early 2026 through the strategic acquisitions of Bako Diagnostics and StrataDx; and Biopharma Services, which offers genomic profiling for clinical trials. Additionally, the company maintains a therapeutic development arm focused on a proprietary oncology pipeline, including clinical candidates FID-007 and FID-022. Fulgent competes directly with specialized genomic firms like Natera, GeneDX, and Myriad Genetics, as well as diversified giants such as Labcorp and Quest Diagnostics. It distinguishes itself through a proprietary bioinformatics platform and heavy integration of artificial intelligence to drive operational efficiencies and lower cost structures relative to legacy competitors. The leadership team is anchored by Founder, Chairman, and CEO Ming Hsieh, a prominent entrepreneur who previously co-founded Cogent, Inc., a biometric identification firm acquired by 3M for $943 million. Hsieh is supported by Chief Financial Officer Paul Kim and President and COO James Xie, both of whom held senior executive roles at Cogent, establishing a long-standing leadership pedigree in scaling high-tech enterprises. The scientific foundation is led by Co-founder and Chief Scientific Officer Dr. Hanlin (Harry) Gao, formerly of City of Hope, and Chief Commercial Officer Brandon Perthuis, who brings extensive experience from Baylor Genetics. The company is characterized by high insider ownership, with Hsieh remaining a primary stakeholder, and a board that includes seasoned industry veterans such as network security pioneer Ken Xie. This executive core has successfully pivoted the company from a COVID-19 testing leader back to its roots in high-complexity genomic and digital pathology services, maintaining a robust cash position of approximately $705 million as of early 2026.